Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients with Type 2 Diabetes

Diabetes

Volumn 50, Issue 7-12, 2001, Pages 2497-2504

  Meier, Juris J ^a,b   Hücking, Katrin ^a,b   Holst, Jens J ^c   Deacon, Carolyn F ^c   Schmiegel, Wolff H ^a   Nauck, Michael A ^a,b,d  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; INSULIN;

ADULT; AGED; ARTICLE; BLOOD; FEMALE; GENETICS; GLUCOSE CLAMP TECHNIQUE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; REFERENCE VALUE; SECRETION;

ADULT; AGED; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; MALE; MIDDLE AGED; REFERENCE VALUES;

EID: 0035512742     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.11.2497     Document Type: Article

References (57)

1. Creutzfeldt W: The incretin concept today. Diabetologia 16:75-85, 1979
2. Creutzfeldt W, Nauck M: Gut hormones and diabetes mellitus. Diabetes Metab Rev 8:149-177, 1992
3. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917, 1993
4. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet 2:1300-1304, 1987
5. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492-498, 1986
6. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307, 1993
7. Nauck MA, Holst JJ, Willms B, Schmiegel W: Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 105:187-195, 1997
8. Göke R, Trautmann ME, Haus E, Richter G, Fehmann HC, Arnold R, Göke B: Signal transmission after GLP-1(7-36)amide binding in RINm5F cells. Am J Physiol 257:G397-G401, 1989
9. Gromada J, Holst JJ, Rorsman P: Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflügers Arch 435:583-594, 1998
10. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-54, 1986
11. Holst JJ, Gromada J, Nauck MA: The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 40:984-986, 1997
12. O'Rahilly SP, Rudenski AS, Burnett MA, Nugent Z, Hosker JP, Darling P: Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familial type 2 diabetes. Lancet 16:360-364, 1986
13. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, Groop L: Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 321:337-343, 1989
14. Vauhkonen I, Niskanen L, Vanninen E, Kainlainen S, Uusitupa M, Laakso M: Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited: metabolic studies on offspring of diabetic probands. J Clin Invest 101:86-96, 1998
15. Köbberlhig J, Tillil H, Lorenz H-J: Genetics of type 2 A- and type 2 B-diabetes mellitus (Abstract). Diabetes Res Clin Pract 1 (Suppl. 1):311, 1985
16. Leahy JL, Bonner-Weir S, Weir GC: β-cell dysfunction induced by chronic hyperglycemia: current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 15:442-455, 1992
17. Jones IR, Owens DR, Moody AJ, Luzio SD, Morris T, Hayes TM: The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia 30:707-712, 1987
18. Krarup T, Saurbrey N, Moody AJ, Kühl C, Madsbad S: Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus. Metabolism 36:677-682, 1987
19. Hücking K, Meier JJ, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA: Reduced insulinotropic effect of gastric inhibitory polypeptide (GIP) in first-degree relatives of type 2 diabetic patients (Abstract). Diabetes 49 (Suppl. 1):A227, 2000
20. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ: Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575-3581, 2000
21. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørrskov C, Ritzel R, Schmiegel WH: Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273:E981-E988, 1997
22. Albareda M, Rodriguez-Espinosa J, Murugo M, de Leiva A, Corcoy R: Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 43:1507-1511, 2000
23. DeFronzo RA, Gunnarsson R, Björkman O, Olsson M, Wahren J: Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type 2) diabetes mellitus. J Clin Invest 76:149-155, 1985
24. Porte D, Kahn SE: Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet β-cell dysfunction. Diabetes 38:1333-1336, 1989
25. Kahn SE, Halban PA: Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 46: 1725-1732, 1997
26. Fritsche A, Stefan N, Hardi E, Häring H, Stumvoll M: Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. Diabetologia 43:852-858, 2000
27. Kubota A, Yamada Y, Hayami T, Yasuda K, Someya Y, Ihara Y, Kagimoto S, Watanabe R, Taminato T, Tsuda K, Seino Y: Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDM: no evidence of association with Japanese NIDDM subjects. Diabetes 45:1701-1705, 1996
28. Almind K, Ambye L, Urhammer SA, Hansen T, Echwald SM, Holst JJ, Gromada J, Thorens B, Pedersen O: Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells. Diabetologia 41:1194-1198, 1998
29. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
30. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C: Cloning and functional expression of the human islet GLP-1 receptor: demonstration that exendin-1 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42:1678-1682, 1993
31. Gremlich S, Porret A, Hani EH, Cherif D, Vionnet N, Froguel P, Thorens B: Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44:1202-1208, 1995
32. Volz A, Göke R, Lankat Buttgereit B, Fehmann HC, Bode HP, Göke B: Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma. FEBS Lett 373:23-29, 1995
33. Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA: Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 50:1004-1011, 2001
34. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D: Diminished B cell secretory capacity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 74:1318-1328, 1984
35. O'Rahilly S, Turner RC, Matthews DR: Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med 318:1225-1230, 1988
36. Elbein S, Hasstedt S, Wegner K, Kahn S: Heritability of pancreatic B-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab 84:1398-1403, 1999
37. Laws A, Stefanick M, Reaven G: Insulin resistance and hypertriglyceridemia in nondiabetic relatives of patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 69:343-347, 1989
38. Lillioja S, Mott D, Spraul M, Ferraro R, Foley J, Ravussin E, Knowler W, Bennett P, Bogardus C: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. N Engl J Med 329:1988-1992, 1993
39. Humphriss DB, Stewart MW, Berrish TS, Barripcanal LA, Trajano LR, Ashworth LA, Brown MD, Miller M, Avery PJ, Alberti KG, Walker M: Multiple metabolic abnormalities in normal glucose tolerant relatives of NIDDM families. Diabetologia 40:1185-1190, 1997
40. van Haeften TW, Dubbeldam S, Zonderland ML, Erkelens DW: Insulin secretion in normal glucose-tolerant relatives of type 2 diabetic subjects. Assessments using hyperglycemic glucose clamps and oral glucose tolerance tests. Diabetes Care 21:278-282, 1998
41. Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Järvinen H, Evron W, Dailey G, Gerich J: Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 273:1855-1861, 1995
42. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
43. Holz GG, Kuhtreiber WM, Habener JF: Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361:362-365, 1993
44. Krarup T: Immunoreactive gastric inhibitory polypeptide. Endocr Rev 9:122-133, 1988
45. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43:535-539, 1994
46. Schirra J, Katschinski M, Weidmann C, Schäfer T, Wank U, Arnold R, Göke B: Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 97:92-103, 1996
47. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M: Exendin (9-39)amide is an antagonist of glucagon-like peptide-1 (7-36)amide in humans. J Clin Invest 101:1421-1430, 1998
48. Jia X, Brown JC, Ma P, Pederson RA, McIntosh CH: Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion. Am J Physiol 268:E645-E651, 1995
49. Tseng C-C, Kieffer TJ, Jarboe LA, Usdin TB, Wolfe MM: Postprandial stimulation of insulin release by glucose-dependent insulinotropic peptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest 98:2440-2445, 1996
50. Nyholm B, Walker M, Gravholt CH, Shearing PA, Sturis J, Alberti KGMM, Holst JJ, Schmitz O: Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of type II (non-insulin-dependent) diabetic parents: evidence of several aberrations. Diabetologia 42:1314-1323, 1999
51. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J-I, Seino Y: Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A 96:14843-14847, 1999
52. Haffner S, Stern M, Hazuda H, Mitchell B, Patterson J: Increased insulin concentrations in nondiabetic offspring of diabetic parents. N Engl J Med 319:1297-1301, 1988
53. Ishikawa M, Pruneda ML, Adams-Huet B, Raskin P: Obesity-independent hyperinsulinemia in nondiabetic first-degree relatives of individuals with type 2 diabetes. Diabetes 47:788-792, 1998
54. Hermans MP, Levy JC, Morris RJ, Turner RC: Comparison of tests of B-cell function across a range of glucose tolerance from normal to diabetes. Diabetes 48:1779-1786, 1999
55. Legro RS, Finegood D, Dunaif A: A lasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 83:2694-2698, 1998
56. Belfiore F, Iannello S, Volpicelli G: Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol Genet Metab 63:134-141, 1998
57. Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh J: A simple measure of insulin resistance. Lancet 346:120-121, 1995